How previous immunity influences immune memory recall and protection against related flaviviruses is largely unknown, yet encounter with multiple flaviviruses in a lifetime is increasingly likely. Using sequential challenges with dengue virus (DENV), yellow fever virus (YFV), and Japanese encephalitis virus (JEV), we induced cross-reactive cellular and humoral immunity among flaviviruses from differing serocomplexes. Antibodies against JEV enhanced DENV replication; however, JEV immunity was protective in vivo during secondary DENV1 infection, promoting rapid gains in antibody avidity. Mechanistically, JEV immunity activated dendritic cells and effector memory T cells, which developed a T follicular helper cell phenotype in draining lymph nodes upon secondary DENV1 infection. We identified cross-reactive epitopes that promote recall from a pool of flavivirus serocomplex cross-reactive memory CD4 T cells and confirmed that a similar serocomplex cross-reactive immunity occurs in humans. These results show that sequential immunizations for flaviviruses sharing CD4 epitopes should promote protection during a subsequent heterologous infection. Fig. 2. Cross-reactive and cross-protective flavivirus immunity. End-point titers of specific versus cross-reactive serum immunoglobulin G (IgG) against (A) DENV1, (B) YFV, or (C) JEV at each time point were measured by enzyme-linked immunosorbent assay (ELISA) for mice infected with DENV1, YFV, or JEV. Blood was collected 7, 14, and 21 days after infection. A comparison of specific versus cross-reactive end-point titers for mice infected with (D) DENV1, (E) JEV, or (F) YFV is presented for serum obtained 21 days after challenge. The avidity of serum antibodies toward each virus after challenge with (G) DENV1, (H) JEV, or (I) YFV is presented. Neutralization of virus by serum anti bodies from mice infected with DENV1, YFV, and JEV or injected with saline was measured by plaque reduction neutralization test (PRNT) against (J) JEV, (K) YFV, or (L) DENV1.
INTRODUCTION
Flaviviral pathogens are primarily transmitted to humans by arthro pod bites (1) . This group is composed of several pathogenic viruses, including Japanese encephalitis virus (JEV), yellow fever virus (YFV), West Nile virus (WNV), dengue virus (DENV), and newly emer gent Zika virus (ZIKV) (2, 3) . The widespread distribution of flavi viruses results in hundreds of millions of infections annually and exposes many more to the risk of disease (1, 4) . Moreover, cocircu lation of multiple flaviviruses in some geographical regions (5) and gains in vaccination coverage for YFV and JEV (6) , combined with the modern surge in human geographic mobility, have increased the likelihood of exposure to multiple flaviviruses within a lifetime. This raises the important question of how preexisting immunity will in fluence the outcome of subsequent vaccination or infection with a heterologous flavivirus.
The genus Flavivirus is composed of nearly 70 known viruses, organized into serocomplexes (7) . Human infection results in produc tion of both virus speciesspecific and flavivirus crossreactive anti bodies (8) . The influence of serocomplex crossreactive immunity during a subsequent flavivirus infection has not yet been clearly de fined; however, several studies suggest that crossreactive antibodies can be protective. For example, primary infection with JEV, YFV, or DENV1 protected animals from a virulent secondary YFV challenge in a hamster model, which was interpreted as showing a protective role for crossreactive antibodies (9) . DENVimmune humans were also observed to experience milder YFV symptoms than DENV naïve individuals (10) , again suggesting a protective role for previous flavivirus exposure during a secondary heterotypic infection.
Although few studies have examined crossreactive immune re sponses among flaviviruses from differing serocomplexes (11, 12) , more is known regarding crossprotection by viruses within the same serotype or closely related virus strains (13, 14) . For example, crossprotection for a new serotype or strain of DENV, when it oc curs, is thought to be achieved primarily through neutralizing anti bodies that mainly recognize epitopes present on the viral envelope glycoprotein surface (15, 16) . In contrast, subneutralizing (due to either antibody quality or concentration) flavivirus crossreactive antibodies are believed to increase the severity of a secondary infec tion due to antibodydependent enhancement (ADE) of infection (17, 18) , a phenomenon that is well supported in the context of re peated infections by DENV serocomplex viruses (19, 20) , as well as JEV serocomplex viruses (21, 22) . ADE occurs when Fc receptors promote internalization of virusantibody immune complexes with in target cells (23, 24) . In vivo, ADE has been shown using an im munocompromised mouse model (25, 26) , yet evidence in humans remains indirect for DENV (27) (28) (29) , although we have recently shown that antibodies against JEV can lead to ADE of the YFV vaccine in humans (30) .
Flaviviruses also induce serocomplex and serotype crossreactive T cell responses (31, 32) . For example, a recent study showed that DENV immunity enhances the kinetics and magnitude of T cell responses to ZIKV during ex vivo stimulation (33) . During heterolo gous DENV infections in mice, crossreactive T cells increase, sug gesting a possible role of T cells in heterologous DENV immunity (34) . Serotype crossreactive T cells have also been identified in hu man DENV cohorts (35, 36) . Some reports suggest an association between crossreactive T cells and severe disease during heterologous DENV infections due to "original antigenic sin" (36) . Yet, more recent evidence has indicated that although there is skewing toward the crossreactive CD8 epitopes for the primary infecting strain during heterologous DENV infection, this crossreactivity does not impair immunity (37) . Thus, flavivirus crossreactive immunity has the po tential to either help or harm the course of immunity to a subsequent infection, but many factors including the degree of genetic similarity, conformation of structural proteins, and existence of cross reactive T cell epitopes all may influence how immunity to one flavivirus can modify the development of immunity and clinical outcome to another.
The mechanisms by which flavivirus crossreactive antibodies or memory T (T MEM ) cells contribute to immune protection or path o logy remain unclear. Here, using an immunocompetent mouse model, we defined experimentally how crossreactive immunity modulates the course of infection during various secondary heterotypic flaviviral challenges. Serocomplex crossreactive responses were also identi fied in humans. Our results suggest novel strategies for promoting crossprotection for flavivirus immunization.
RESULTS

Serocomplex cross-reactive immunity elicited by flaviviruses
To assess the influence of preexisting crossreactive immunity on the development of immunity to a subsequent flavivirus challenge, we chose three representative pathogens from independent serocomplexes: JEV (SA14142), YFV (YFV17D), and DENV1 (EDEN1). Considering the overlapping geographical distribu tions of these viruses ( Fig. 1 , A to C) and their genome similarity (with each other and recently emerged pathogens, WNV and ZIKV; Fig. 1D ), we expected that the viruses would elicit crossreactive im munity, experimentally mimicking the serocomplex crossreactive responses of humans (8) . Immunocompetent mice were chosen be cause the primary objective was to study functional immune re sponses. The strains chosen for YFV and JEV are liveattenuated vaccine strains, while the DENV1 strain is a clinical isolate, also chosen because these are the challenges most likely to be experi enced by humans currently, where YFV and JEV vaccinations are becoming more common than natural infections, but natural DENV exposure remains high. We infected groups of mice with each virus and quantified specific and serocomplex crossreactive antibody titers generated ( Fig. 2 , A to C). DENV1infected animals produced hightiter DENV1specific antibody ( Fig. 2 , A to C) and lowtiter crossreactive antibodies against JEV but did not induce crossreactive antibodies against YFV (Fig. 2 , D to F). In general, immunization with YFV and JEV vaccine strains produced lower concentration specific antibodies compared to an equivalent inocu lation with the clinical isolate of DENV1 ( Fig. 2 , A to C). Both YFV and JEV immunizations were able to produce hightiter cross reactive antibodies against DENV1 (Fig. 2 , D to F), raising the po tential that these antibodies could influence the course of secondary flavivirus infection.
To test the quality of the antibodies elicited, we measured their avidity to the virus structural antigens for each homologous or het erologous virus combination. The DENV1 clinical isolate induced highavidity specific but lowavidity crossreactive antibodies against YFV and JEV ( Fig. 2 , G to I). However, for JEV and YFV vaccine strains, both specific and crossreactive antibodies generated were low avidity ( Fig. 2 , G to I). We next tested the capacity of se rum from mice challenged with DENV1, YFV, or JEV to neutralize each virus and found that they were neutralizing against the prima ry challenge strain but not against the other related flaviviruses ( Fig. 2 , J to L). Thus, our mouse model results are consistent with the classification of DENV, JEV, and YFV into the same discrete serocomplexes as is observed in humans (8) .
To measure crossreactive cellular responses, peptide antigens were derived from infected cells and thus contain both structural and nonstructural antigens. Splenocytes showed robust prolifera tion when reexposed to antigens from the same viruses used to prime mice ( Fig. 2M ). Splenocytes from YFV and JEVprimed mice also proliferated upon exposure to both DENV1 and JEV anti gens ( Fig. 2M ). However, splenocytes from DENV1infected mice only proliferated in response to JEV, but not YFV, antigens (Fig. 2M) . Similarly, YFV, but not DENV1, antigen induced significant prolif eration of JEVprimed splenocytes (Fig. 2M ). These results support the idea that both serocomplexspecific and crossreactive cellular immunity occur. Cumulatively, our mouse model recapitulates the crossreactive immunity that characterizes human flavivirus infec tion, allowing further interrogation of the mechanisms that regulate immune priming or pathology during a secondary heterologous challenge.
The influence of cross-reactive immunity on subsequent flavivirus infection
To test whether preexisting crossreactive immunity could reduce the viral burden during a secondary homologous or heterologous challenge, mice were challenged with DENV1, YFV, or JEV or given a vehicle control injection. To dissect the contributions of each adaptive immune branch to infection clearance, serum and T cells were collected and passively transferred to naïve mice. Recipient mice were infected subcutaneously with DENV1, 24 hours after transfer, followed by quantification of viral load in the draining lymph nodes (LNs) after another 24 hours, as subcutaneously in jected DENV progresses to systemic infection via LNs in primates and mice (38, 39) . As expected, adoptive transfer of serum or T cells from DENV1immune mice or true secondary infection all led to a reduced viral burden upon DENV1 challenge, compared to transfer of those products from naïve (mockimmunized) animals ( Fig. 2N) , consistent with the belief that homologous secondary infections are efficiently cleared (28) . However, transfer of serum or T cells from YFVimmunized mice or T cells from JEVimmunized mice did not influence the viral load ( Fig. 2N ). Mice given serum from JEV immunized animals showed significantly enhanced viral burden in LNs after secondary heterologous DENV1 challenge ( Fig. 2N ), po tentially attributable to ADE of DENV1 by antibodies generated during JEV immunization. In contrast, the viral load was signifi cantly reduced in JEVimmune mice after a true secondary DENV1 infection ( Fig. 2N ). YFV immunity did not affect DENV1 clearance (Fig. 2N ). The protective influence of JEV, but not YFV, immunity on DENV infection that was observed early at 1 day after infection ( Fig. 2N ) also persisted to later time points, as shown in LNs at 3 days after secondary cutaneous infection ( fig. S1 ). Together, our data suggest that both humoral and cellmediated crossreactive immu nity developed during a primary infection have the potential to be protective during secondary homologous or heterologous flavi virus infection by promoting viral clearance.
Cross-reactive antibodies can prime for early neutralizing immunity
Having observed that heterologous priming is protective during a secondary flavivirus challenge, we proceeded to evaluate how crossreactive antibodies influence the development of adaptive re sponses during a secondary heterologous infection. Specifically, we questioned whether previous flavivirus infection might influence the production of neutralizing antibodies during memory recall. Mice were challenged with DENV1, YFV, JEV, or saline, and after 70 days, serum was collected to test its DENV1neutralizing capac ity. Mice were then rechallenged with DENV1, and serum was har vested after another 5 days to measure DENV1 neutralization. Sera obtained before secondary infection showed similar serotype specific neutralization (Fig. 3, A and B) , as in Fig. 2 . Neutralization of DENV1 was improved after a secondary homologous DENV1 challenge ( Fig. 3 , C and D). JEVimmune mice also strongly neu tralized DENV1 after a secondary DENV1 challenge at higher levels than DENV1challenged mice that were previously flavivirusnaïve (saline control; Fig. 3 , D and E). However, sera from mice that expe rienced a primary YFV challenge and secondary DENV1 challenge did not show improved neutralization of DENV1 ( Fig. 3 , C and E). These results suggest that JEVinduced crossreactive immunity augments neutralizing antibody responses during a secondary flavi viral challenge.
Next, we measured the avidity of antibodies generated against DENV1 in each of the primary immune experimental groups (saline, DENV1, JEV, and YFV), which were also given a secondary DENV1 challenge. Consistent with the results observed with the PRNT re sults, antibodies generated after a true homologous secondary in fection with DENV1 had high avidity against DENV1 antigen ( Fig. 3F) . Similarly, antibodies generated in JEVimmune mice after a secondary DENV1 challenge showed significant improvement in their avidity against DENV1 antigen ( Fig. 3F ), while primary infec tion with YFV did not lead to improved avidity compared to the control group ( Fig. 3F ). At the same time point of 5 days after infec tion when the functionality of antibodies has improved ( Fig. 3 , D to F), protection is observed in terms of reduced DENV1 infec tion in the spleens of JEVimmune mice ( Fig. 3G ). JEV vaccination is able to prime a certain level of protection against an infection with DENV1.
JEV immunity primes for DC and T cell activation during DENV infection
Having shown that JEV can prime for functional protection against a subsequent infection with DENV1, we sought to understand the mechanism behind this. We hypothesized that JEV immunity may improve the mounting immune response during secondary DENV1 challenge by enhancing activation of dendritic cells (DCs), because DCs, as Fc receptor-bearing cells, could potentially bind to immune complexes formed during the heterologous secondary DENV challenge. To test this, mice were immunized with YFV, JEV, or saline, followed by a secondary challenge with DENV1 in the footpad skin. At 24 hours after challenge, DC activation was quanti tated in draining LNs. The group with primary immunity to YFV showed similar levels of DC activation after DENV1 infec tion, compared to the saline control group, but there was a marked increase in the number of activated DCs in draining LNs after sec ondary DENV1 challenge in JEVimmune mice ( Fig. 4A and fig.  S2 , A and B).
To better understand the role of T cells during DENV infection of JEVimmune mice, we examined the activation of various T cell populations in the draining LN. A flow cytometry gating strategy was used, where CD4 + and CD8 + T cell populations were further defined as naïve (T N ; CD44 − CD62L + ), effector (T eff ; CD44 − CD62L − ), effector memory (T EM ; CD44 + CD62L − ), and central memory (T CM ; CD44 + CD62L + ) T cells ( Fig. 4B ). CD69 was used to assess acti vation. We observed that the ratio of activated CD8 + and CD4 + T N cells to T EM cells was significantly reduced in the JEVimmunized group during a secondary DENV1 challenge ( Fig. 4C ). Although no change was observed in the YFVimmunized group in terms of the relative numbers of activated CD4 + T EM to T N cells, activated CD8 + T EM cells were significantly increased relative to T N cells upon sec ondary DENV1 challenge ( Fig. 4C) , demonstrating that the memory recall response favored the activation of T EM over T N cells. Similar ly, the total T N CD4 + and CD8 + T N cells remained unchanged for the YFVimmunized group compared to the saline control group during DENV1 infection ( fig. S2C ). Total CD8 + T N cells in the JEVimmunized group did not differ compared to the saline control group; however, CD4 + T N cells were significantly reduced upon sec ondary DENV1 challenge ( fig. S2C ). Both YFV and JEV increased the numbers of T eff cells in LNs (Fig. 4D ), but T MEM cells were dif ferentially influenced during secondary DENV1 challenge ( Fig. 4 , E and F). Specifically, activated CD4 + and CD8 + T CM cells were also significantly reduced in both YFV and JEVimmunized groups compared to the control group (Fig. 4E ). In contrast, total numbers of activated CD4 + and CD8 + T EM cells were only significantly in creased in the JEVimmunized group but not in the YFV immunized group (Fig. 4F ). To verify functional activation after a secondary heterologous challenge, we intracellularly stained T EM cells for the cytokines interleukin2 (IL2) and interferon (IFN), both of which were expressed at higher levels by T EM cells of DENV1 or JEV immune animals after a secondary DENV1 challenge (Fig. 4 , G and H). Thus, T cell responses to DENV1 infection are modulated by previous immunity to JEV and YFV to differing extents. Previous JEV exposure can prime for heightened DC activation and also im prove T EM cell function during a subsequent DENV1 challenge, while neither of these indicators of effective immune activation was influenced by previous YFV exposure.
Presumably, T MEM cells are recalled and enter LN follicles during challenge by a heterologous serocomplex. To address this hypothesis, we adoptively transferred T cells from Thy1.2 + donor mice, which were isolated 5 weeks after flavivirus challenge (from either DENV1, JEV, or YFVimmune mice) into Thy1.1 + recipient mice. The recip ient mice were then challenged with DENV1 subcutaneously, and the draining LNs were harvested 6 days after infection. LN cells were stained for donor T follicular helper (T fh ) cells with a memory phe notype (Thy1.2 + CD4 + CD44 + CD62 −/lo PD1 + CXCR5 + BCL6 + ). As ex pected, T fh cells with a memory phenotype were more abundant in LNs of DENV1 and JEVimmune mice compared to naïve mice ( Fig. 4I ), indicating a genuine recall of flavivirusexperienced T MEM cells to participate in the germinal center reaction as T fh cells.
Identification of DENV-specific and flavivirus cross-reactive CD4 epitopes
A plausible explanation for the increased crossprotection of JEV compared to YFV toward DENV could be its higher degree of ge nome similarity ( Fig. 1D ). To explore this possibility and further define how the genetic relationships between flaviviruses could in fluence T MEM activation, we examined the predicted CD4 epitopes along the DENV fulllength polyprotein. Bioinformatic approaches identified 17 regions of the DENV polyprotein significantly likely to be presented on mouse major histocompatibility complex class II (MHCII) (IAb; Fig. 5A and table S1): one in capsid, one in NS1, two in NS2b, seven in NS3, two in NS4b, and four in NS5. For these DENV1 peptides, we investigated whether the same region of JEV or YFV was also significantly likely to be presented on MHCII. This analysis showed that most of the peptides were exclusive to DENV, with probability scores falling below cutoff levels, and only one sequence was predicted by this method to bind to MHCII for all three viruses (Fig. 5A ). Because of its higher degree of homology, JEV shared more sequences that were predicted to bind MHCII with DENV than YFV, approximately 41% of predicted peptides for JEV versus 12% for YFV ( Fig. 5A ). To validate the predicted DENV1 CD4 epitopes and to assess whether these peptides could induce proliferation of CD4 + T MEM cells (CD3 + CD4 + CD44 + ) from JEV or YFVimmune animals, we performed a proliferation assay. DENV peptides were chosen from those regions that were also predicted to be presented during JEV infection exclusively (but not YFV infec tion; Fig. 5B ), YFV infection exclusively (but not JEV infection; Fig. 5C ), or both infections ( Fig. 5D ). Alignments of these DENV peptides with the corresponding JEV and YFV sequences reveal varying degrees of homology and high levels of homology with ZIKV ( Fig. 5, B to D). The selected peptides were used to pulse antigenpresenting cells (APCs), which were subsequently exposed to splenocytes from DENV1immune animals. After incubation, the cells were stained for flow cytometry analysis of the frequency of CD4 + T MEM cells to identify any stimulatory effect on this subset. Of the six DENV1 peptides chosen for validation, five induced expansion of T MEM cells from DENV1immune animals ( Fig. 5E) . Surprisingly, the one peptide that was predicted to bind MHCII for DENV and also for the homologous regions in JEV and YFV ( Fig. 5D ) did not cause T MEM cell expansion in splenocytes from animals immune to DENV1, JEV, or YFV, suggesting that it may not be a true epitope that leads to CD4 + memory formation ( Fig. 5E ). Of the peptides corresponding to regions of JEV that were also predicted to bind to MHCII, 80% also induced proliferation of T MEM cells from JEV immune animals, demonstrating crosspriming of JEVspecific memo ry cells by DENV peptides (Fig. 5E ). One of these corresponded to a region of YFV that was not significantly predicted to bind MHC II (although approaching significance), but it shared a higher than average degree of homology to DENV and the other flaviviruses. This peptide also induced enrichment of T MEM cells and appeared to be a region broadly capable of crosspriming (Fig. 5E ). Surpris ingly, a DENV1 peptide that, similarly, corresponded to a YFV re gion predicted to bind to MHCII, where the analogous region of JEV did not (Fig. 5C ), induced expansion of JEV, but not YFV, postimmune T MEM cells (Fig. 5E ). Proliferation was confirmed by staining for Ki67 ( fig. S4, A and B) . Intracellular staining for IFN and an IFN enzymelinked immunospot (ELISPOT) assay con firmed functional activation of specific and crossreactive T cells by these peptides (fig. S4 , C to G). Therefore, we have identified epi topes that are crossreactive and allow T MEM recall from a pool of fla vivirus serocomplex crossreactive memory cells.
Serocomplex cross-reactive T MEM cells are present in humans
To validate whether flavivirusimmune humans also have serocom plex crossreactive CD4 T MEM cells that can be reactivated by a new flavivirus, we recruited donors with a known history of JEV vacci nation. PRNT assays were used to confirm immunity against DENV, JEV, YFV, or ZIKV (Fig. 6, A to D) . ZIKV was added to the study because the donors were recruited in Singapore, which has a high prevalence of natural DENV immunity that could limit our ability to focus on DENV crossreactive responses in JEVimmune donors. Two donors appeared to have neutralizing antibodies against both JEV and DENV (Fig. 6, B and C), while one had neutralizing anti bodies only to JEV (Fig. 6D ). Similar to mice (Fig. 2) , cross reactive antibodies were generated, because all JEVimmune donors showed crossreactive immunity to ZIKV (Fig. 6 , E and F). How ever, those antibodies did not detect more distantly related YFV (Fig. 6 , E and F). Also, as observed in mice, the crossreactive avidity was weaker (here, against ZIKV) compared to the specific avidity (against JEV; Fig. 6G ). To validate that T MEM cells could be cross activated by an tigens from differing serocomplexes, donor peripheral blood mono nuclear cells (PBMCs) were stimulated with viral antigens. By flow cytometry, we observed increased activation of the human CD4 T EM (CD3 + CD4 + CD45RO + CCR7 − CD62L + ) population, indicated by upregulation of the activation marker human leukocyte antigen (HLA)-DR after incubation with JEV antigens for cells from JEV immune donors but not from the naïve control ( Fig. 6 , I to K). Fur thermore, both YFV and ZIKV antigens induced crossactivation of T EM cells (Fig. 6 , J to L). ELISPOT assays were used to validate activation by measuring IFN production after exposure of T cells to antigens from heterologous challenges ( Fig. 6 , L to O). This con firmed a functional crossactivation because JEV immune patients produced IFN in response to heterologous challenges of ZIKV ( Fig. 6 , M to O), and for one patient, IFN was also produced in re sponse to YFV (Fig. 6M ), to which they had not been exposed. There fore, crossactivation of T MEM cells from flavivirusimmune humans can occur upon exposure to a virus from a differing serocomplex.
DISCUSSION
Our studies demonstrate the key contributions of serocomplex crossreactive antibodies and T cells toward priming for enhanced immunological memory during a secondary flavivirus challenge. In the context of the substantial number of flavivirusimmune individ uals and the cautious approach to vaccination that is taken in re sponse to the possibility of crossreactive immune pathology (11) , this work provides a detailed understanding of how immunity influences a subsequent immunization or infection by a new flavi virus. Studies examining functional responses during a second ary heterologous challenge frequently assume that antibodies are the most consequential immune determinant for mediating cross reactive protection, when it occurs (40, 41) . However, we ob served antibodymediated enhancement of virus in a secondary tar get organ, the LN, when serum alone was transferred to recipient mice before a secondary challenge with a flavivirus from a distinct serocomplex (here, JEV followed by DENV infection; Fig. 2N ). This is consistent with the concept of ADE. We reported that sequential immunization of humans with inactivated JEV vaccine followed by liveattenuated YFV vaccine resulted in higher YFV viremia than controls with no previous JEV vaccination (30) . That enhancement of DENV1 infection was observed when mice were transferred se rum from JEVimmune, but not YFVimmune, animals (Fig. 2N) indicates that the degree of genome similarity (Fig. 1D ) might play a role in the potential of ADE. In contrast, JEVimmune mice that experienced a true primary infection, followed by a secondary in fection with DENV1, had improved viral clearance in LNs (Fig. 2N ). This observation cautions against assuming that T cell responses are dispensable for crossprotection against a secondary flavivirus infection. Rather, we observed that optimal memory recall relies on a combination of antibodies and T cells.
Our data suggest that increased DC presentation due to cross reactive antibodies, combined with effective crossreactive responses in the CD4 memory effector compartment, enhances protection observed with secondary challenge of DENV1, although YFV im munization did not result in a significant increase in DC activation in the draining LNs during secondary DENV1 challenge compared to the control group (Fig. 4A) . That there was more efficient T EM recall over T N activation for CD8 + T cells from YFVimmune ani mals suggests some degree of crossreactive T cell immunity in vivo in mice (Fig. 4, C and F) . However, this crossreactive response was not sufficient to protect significantly during DENV1 challenge (Figs. 2N and 3G and fig. S1 ). In humans, a heterologous CD8 T cell response also characterizes reinfection within the DENV serocom plex and, in one study, did not appear to be associated with more severe disease (37) . Our results are consistent with that observation because crossreactive CD8 T cells were not harmful in our model. We also observed that splenocytes from YFVimmunized mice pro liferated in response to DENV1 antigen (Fig. 2M) , despite not observing a crossreactive functional protection against DENV1 chal lenge ( Figs. 2N and 3G and fig. S1 ). In contrast, JEVimmunized mice displayed significant gains in DC activation and improved ef ficiency of the memory recall response because the ratio of activated T N /T EM cells decreased in JEVimmune mice compared to control mice for both CD4 + and CD8 + T cells (Fig. 4C ). Furthermore, adop tive transfer experiments showed that, following a DENV challenge, T MEM cells from JEVimmune donors adopt a T fh cell phenotype similar to T cells from DENVimmune donors (Fig. 4I) , supporting both memory recall and participation in the germinal center reaction.
The in vivo evidence of T EM recall in JEVimmune animals with a challenge by DENV1 led us to identify and validate several pre dicted CD4 + epitopes for DENV1. Predicted epitopes were identi fied using bioinformatics, followed by validation in proliferation assays, where flow cytometry was used to verify the specific expan sion of CD4 T MEM cells. As predicted, JEV and DENV shared five functionally crossreactive epitopes, while all three viruses (DENV1, JEV, and YFV) shared only one highly crossreactive epitope (Fig. 5E ). This likely explains why JEVimmune mice show en hanced clearance of DENV1 ( Fig. 2N ) and substantial gains in anti body avidity and neutralization against secondary DENV1 (Fig. 3 , D to F). While it is also likely that differences in antigen persistence between JEV and YFV could influence the quality of crossreactive responses, we note that each infection induced hightiter neutraliz ing responses to itself (Fig. 2 , A to C) and significant activation of homologous T cells (Fig. 2M) , indicating efficient memory induc tion. This supports the findings that the differences between YFV and JEV in terms of T cell epitopes shared with DENV1 were due to a genuine lack of crossactivation of YFVimmune cells by most DENV1 epitopes. Because CD4 + T cells are key for providing B cell help and refining antibody responses, the unique capacity of JEV to induce heightened numbers of activated CD4 + T EM cells (Fig. 4F ) could be responsible for the enhanced DENV1binding capacity of antibodies generated immediately following a secondary DENV1 infection. Further studies are also needed to examine how CD4 T EM cells influence CD8 T cell responses because T cell help could also be provided to CD8 cells. We validated that T EM cells from JEV or DENV/JEVimmune donors are crossactivated by related flavi viruses ZIKV and YFV (Fig. 6) , although because humans have highly varied MHCII molecules, the crosspresented epitopes are likely to differ from donor to donor. In our mouse challenges, we also observed that the attenuated JEV and YFV vaccine strains induced more crossreactive antibodies in mice than the virulent DENV1 clinical isolate. This could potentially be attributed to mutations that might have been acquired on the surface glycoproteins of YFV and JEV vaccine strains in the process of attenuation (42) . To our knowledge, that vaccination induces weaker avidity antibodies than a virulent infection has not been previously suggested and should be further investigated in humans.
Our findings are also informative in the context of the aim to develop and adopt a broadly effective DENV vaccine. Although multiple strategies have been proposed, such as viruslike particles, attenuated strains, and chimeric viruses (43, 44) , most have aimed to develop a tetravalent vaccine to generate neutralizing antibodies to all DENV serotypes concurrently. The approved Sanofi Pasteur vaccine is based on using the YFV backbone to display DENV structural proteins. The rationale for using YFV as the backbone for a chimeric DENV vaccine was the genome stability of YF17D (45, 46) . YF17D, itself, also has nearly unmatched efficacy as a vaccine, being capable of conferring recipients with lifelong immunity to YFV (47) . In part, this high degree of efficacy is attributed to the ability of YF17D to generate a robust specific CD4 + T cell response (48) . However, questions remain regarding whether the YFVdirected cellular response prompted by YF17D is efficient in priming DENV immunity in humans, because efficacy of the chimeric vaccine was limited in clinical trials, with protection from DENV between 30 and ~65% in the results published to date (49, 50) . Our data show that preexisting immunity to JEV is more effective than YFV immunity in priming recall of T EM cells (Fig. 4F ). That this translates into an increased efficiency of priming for DENV specific antibodies ( Fig. 3 ) and protection against DENV challenge (Fig. 2N ) raises the potential that a JEV vaccine strain might be a more effective backbone for a chimeric DENV vaccine than YFV. Alternatively, validated crossreactive CD4 epitopes could be added to an otherwise successful vaccine backbone such as YF17D to generate broad flavivirus crossreactive responses. Although humans have differing and more diverse CD4 epitopes than inbred mice, in both cases, the degree of genome similarity between DENV and JEV would make conservation of epitopes more likely between these two. Given the importance of nonstructural proteins to generating T cell responses, we expect that liveattenuated vaccines rather than inactivated or subunit vaccines would be more likely to generate functionally protective crossreactive T cell responses. Furthermore, although our work suggests that the degree of virus similarity is important for crossprotection by increasing the likelihood that memory CD4 T cell epitopes would be similar between the primary and secondary challenge strains, we cannot fully predict how all combinations of unique virus strains might behave in vivo.
Here, we show that mice evoke similar immune responses to flaviviruses as humans in terms of generating immunity consistent with human serocomplexes, where crossreactive antibodies are nonneutralizing and have low avidity. Although the use of IFN deficient mouse models are generally favored by the flavivirus field due to the viruses reaching high serum titers and the mice experi encing severe disease, they may be less ideal for studying immunity. IFN has a central role in T cell polarization (51) . Type I IFNs are key for function of plasmacytoid DCs and generating antibody re sponses (52, 53) . Both type I and II IFNs promote antibody class switching and have an adjuvant effect during infection (53, 54) . Studies have emphasized the importance of antibody subclasses to DENV functional immune responses (55) (56) (57) , making this an im portant justification for using an IFNsufficient system to study DENV immunity. On the basis of these considerations, we have used an immunocompetent mouse model to investigate crossreactive immunity among flaviviruses and have identified T MEM responses as a key component of crossprotection. By validating that serocom plex crossreactive T cells are present in humans (Fig. 6) , we have an indication that the mouse and human are similar in terms of dis playing a potential for flavivirus crossprotective CD4 T cell responses.
There are major obstacles to improvement, development, vali dation, safety testing, production, and compliant use of vaccines against the many established flaviviral pathogens that cluster to dis crete serocomplexes, including DENV, YFV, JEV, and WNV, as well as newly emerging pathogens, such as ZIKV. Approaches to rational design of vaccines that provide crossprotection through in troduction of crossreactive CD4 + epitopes may lessen the risk of infection in naïve individuals, in unvaccinated individuals, or to emerging pathogens from this genus. This study identifies novel correlates of protection based on the combined responses of T MEM cells and antibodies during a secondary heterologous flavivirus chal lenge. The results emphasize that crossreactive flavivirus immunity is likely to prime for effective secondary responses but that crossreactive CD4 + T cell responses are key for optimal enhanced secondary im munity to a heterologous infection. These results have implications for rational vaccine design for existing and emerging flaviviral pathogens.
MATERIALS AND METHODS
Mouse infections and immunizations
C57B/6NTac mice were obtained from InVivos. B6.PLThy1a/CyJ mice (Thy1.1 + ) were obtained from The Jackson Laboratory. For intra peritoneal infections, mice were inoculated with 1 × 10 6 PFU of DENV1, JEV, or YFV in 100 l of phosphatebuffered saline (PBS). For subcutaneous infections, mice were injected with 1 × 10 5 PFU in a 20l volume of PBS. Animals were bred and housed in the Duke-National University of Singapore (NUS) vivarium. The SingHealth Institutional Animal Care and Use Committee approved all animal protocols.
Human JEV-immune donors
Human donors that either were suspected flavivirusnaïve or had a known JEV immunization history were recruited as blood donors according to protocols approved by the Centralized Institutional Review Board of Singapore General Hospital.
Virus production DENV1 (D1/SG/05K2402DK1), JEV (SA1414), and ZIKV (H/PF/ 2013) were produced in C6/36 mosquito cells in RPMI 1640 with 2% fetal bovine serum (FBS) and 1% penicillin and streptomycin at 28°C and harvested 5, 3, and 4 days after infection, respectively. YFV (YFV17D) was produced in Vero cells in Dulbecco's modified Eagle's medium with 2% FBS and 1% penicillin and streptomycin at 37°C, with 5% CO 2 , and harvested 3 days after infection. Viral titers were quantified by a standard plaque assay using BHK21 cell mono layers, as described previously (39) .
Evaluation of serum antibody responses
To quantify the virusspecific or crossreactive antibodies in serum, DENV1, YFV, JEV, or ZIKV were purified for use as ELISA capture antigens. In brief, supernatants of infected cells were clarified by centrifugation at 2500 rpm for 10 min and filtered using a 45m filter unit. The virus supernatants were then concentrated by ultra centrifugation (20,000 rpm for 2.5 hours). The pellets were resus pended in PBS, left for 2 hours on ice, and then applied to a 30% sucrose cushion and centrifuged at 25,000 rpm for 4 hours. After removing the supernatants, virus pellets were dried a few minutes before overnight rehydration in PBS. The resuspended viruses were stored at −80°C. Concentrations of viral proteins were measured using a Bradford assay (BioRad) before coating of ELISA plates at a concentration of 5 g/ml. Serum endpoint titers against the vari ous viruses were measured with a standard ELISA, using alkaline phosphatase-conjugated antimouse or antihuman detection anti bodies, based on published protocols (58, 59) . The endpoint titer was calculated at twofold over naïve serum. For avidity ELISAs, washing was performed with either normal wash buf fer or wash buffer containing urea (Sigma) at a 5 M concentration. The percent age of antibody that remained bound after stringent washing was calculated for each sample compared to normal wash conditions. For PRNT assays, 2 × 10 5 BHK21 cells per well were seeded in 24well plates with RPMI 1640 supplemented with 10% FBS and 1% penicillin and streptomycin. Cells were incubated until con fluent at 37°C with 5% CO 2 . Sera from infected mice were heat inactivated for 30 min at 56°C and serially diluted from 1:10 to 1:2560. Each dilution or control was mixed with virus (750 PFU/ml) in a ratio of 1:1 and incubated for 1 hour. Solutions of virus and serum (200 l) were then added to the plates in duplicate and incu bated for 1.5 hours at 37°C with 5% CO 2 . The plates were washed with PBS once, and 500 l of carboxymethylcellulose overlay was added to each well. After 5 days for DENV1 and ZIKV or 3 days for YFV and JEV, the plates were fixed in paraformaldehyde (PFA) be fore staining with crystal violet. The plaques were counted, and the percentage of neutralization was calculated relative to the untreated virus control.
Flow cytometry to assess DC and T cell activation
To quantify activated DCs and T cell subsets after homologous or heterologous secondary infection, mice were injected subcuta neously with 1 × 10 5 PFU of JEV, YFV, or saline control, and after 21 days, all groups were rechallenged with 1 × 10 5 PFU of DENV1 subcutaneously in footpads. Draining popliteal LNs were isolated after an additional 24 hours (n = 6 per group), minced, and incubated in medium containing collagenase (Sigma). Singlecell suspensions were prepared using 70m nylon cell strainers (Falcon). Cells were blocked with 1% bovine serum albumin (BSA) in PBS (Gibco). To quantify DCs, cells were stained with antiCD11c-Pacific Blue (Thermo Scientific), antiCD80-BV605 (BD Biosciences), and anti CD86-BV510 (BD Biosciences). To quantify T cells, cells were stained with antiCD3e-PerCP (peridinin chlorophyll protein) Cy5.5, antiCD4-BV650, antiCD8-AF700, antiCD44-BV510, anti CD62L-PE (phycoerythrin)-Cy7, and antiCD69-FITC (fluorescein isothiocyanate) (all from BD Biosciences). After washing, samples were fixed with 3.7% PFA and analyzed using a Fortessa flow cyto meter (BD Biosciences) and FlowJo software. For some experiments, intracellular staining was performed subsequent to fixation. After PFA treatment, the cells were washed once with PBS-1% BSA and resuspended in PBS containing 1% BSA and 0.1% saponin for 15 min, followed by staining with antimouse IFN-BV711 antibody (BD Horizon, reference 564336) and/or anti-IL2-BV421 (BD Biosciences) in PBS with 1% BSA and 0.1% saponin. After washing, data were acquired by flow cytometry, as above.
T cell adoptive transfers
C57Bl/6 mice (Thy1.2 + ) were challenged with DENV1, JEV, and YFV (five mice per group) by intraperitoneal injection with 1 × 10 6 PFU or injected with saline. Five weeks after infection, the spleens were collected and the total T cells were purified by magnetic col umn using the Pan T Cell Isolation Kit II (mouse; MACS Miltenyi Biotec). C57Bl/6 mice (Thy1.1 + ) received an adoptive transfer by tail vein injection of 1 × 10 6 total T cells per mouse, with either T cells purified from mice exposed to DENV1, YFV, JEV, or saline. The mice were challenged with DENV1 24 hours after transfer, and after 6 days, popliteal LNs were collected and prepared as singlecell suspensions for flow cytometry. The cells were stained using the fol lowing primary conjugated antibodies: antiThy1.2-PerCP Cy5.5 (BioLegend), antiCD4-BV650, antiCD8-AF700, antiCD44-BV510, antiCD62L-PECy7, CD69FITC (all from BD Biosciences), anti Bcl6-AF647 (BioLegend), anti-PD1-BV711 (BioLegend), and anti CXCR5-BV421 (BioLegend).
Proliferation assays
Mice (four groups of n = 5) were intraperitoneally injected with 1 × 10 6 PFU of DENV1, YFV, JEV, or the same volume of PBS. Spleens were collected from mice 5 weeks after infection, injected with 500 l of (10 mg/ml) collagenase in RPMI 1640, and incubated for 30 min at 37°C. Singlecell suspensions were then made using a 70m cell strainer and an excess volume of PBS. Red blood cell lysis buffer [0.15 M NH 4 Cl, 10 mM NaHCO 3 , and 0.1 mM EDTA (pH 7.3)] was then used to treat the isolated cells, followed by washing and adjustment to a concentration of 1 × 10 5 cells/ml. JAWSII cells were preseeded 24 hours before the experiment at 5 × 10 3 cells per well in minimum essential medium, with 20% FBS, 1% penicillin and streptomycin, and granulocytemacrophage colony stimulating factor (GMCSF) (5 ng/ml; Sigma). Antigens for DENV1, JEV, or YFV were prepared according to a published protocol (60) . In brief, Vero cells were infected with DENV1, YFV, or JEV and harvested with a cell scraper when showing 50% cyto pathic effect. Uninfected Vero cells were used to generate control antigens. Cell pellets were extensively washed before and after fix ing with 0.025% glutaraldehyde. The suspensions were sonicated and clarified, and the antigens were stored at −20°C until use. Anti gens (1.5 g/well) were preincubated with JAWSII cells for 48 hours and then treated with mitomycin C (25 g/ml) for 25 min, followed by washing to remove excess mitomycin C. Alternatively, synthetic peptides (synthesized by SABio; 2.5 g/well) were preincubated with JAWSII cells. Purified splenocytes (100 l of 1 × 10 5 cells/ml) were added to each well without pooling of cells so that each repli cate represented the results from an individual mouse. After 72 hours, proliferation was measured using CellTiter 96 AQueous One Solution (Promega), according to the manufacturer's instructions. For pep tide proliferation assays, cells were prepared for flow cytometry analysis of T MEM cells with a staining and analysis strategy as described above, with the addition of the antibody anti-Ki67-BUV395 (BD Biosciences).
Mouse ELISPOT assays
Spleens were harvested from mice injected with saline or DENV1, YFV, or JEV 5 weeks after challenge and treated with collagenase to obtain singlecell suspensions. One million splenocytes per well were seeded in a 96well plate and stimulated with synthetic peptides AAIFMTATPPGSVEA or ASAWTLYAVATTIIT (25 g/ml) for 48 hours at 37°C with 5% CO 2 . The peptidestimulated or control splenocytes were then transferred to 96well IFN ELISPOT plate (BD Biosciences, catalog no. 552569) and incu bated for an additional 17 hours before detection following the manufacturer's instructions. Spotforming cells were enumerated by counting.
Quantification of DENV1 infection in LNs and spleen
Mice were infected with DENV1 28 days after a primary infection with DENV1, YFV, JEV, or mock infection, or 24 hours after adop tive transfer of either antibodies or T cells purified from DENV1, YFV, or JEV postimmune mice. For adoptive transfer experiments, groups of five mice were intraperitoneally injected with PBS control or 1 × 10 6 PFU of DENV1, YFV, or JEV. For serum isolation, blood was collected by intracardiac puncture 28 days after infection. Sera from mice in the same primary infection group were pooled. Recip ient mice (n = 5 per group) received 100 l of serum. Alternatively, spleens were collected 5 weeks after infection of groups, as de scribed above, and the total T cells were extracted using the Pan T cell Isolation Kit and LS magnetic columns (both from Miltenyi), according to the manufacturer's instructions. For each group (n = 5), 1 × 10 6 T cells in PBS were given by tail vein injection into naïve mice. For all groups of mice infected via the subcutaneous route, the infection challenge was established by footpad injection of 1 × 10 5 of DENV1. After 24 hours, the draining popliteal LNs were collected, and RNA was extracted using the RNeasy Mini Kit (Qiagen). The iScript cDNA Synthesis Kit (BioRad) was used according to the manufacturer's instructions with an added DENV1 primer (5′CT GAGTGAATTCTCTCTACTGAACC3′) to ensure conversion of viral RNA to complementary DNA (cDNA). RTPCR was per formed using SYBR Green reagent (BioRad) and validated DENV1 specific primers (forward, 5′CAAAAGGAAGTCGTGCAATA3′; reverse, 5′CTGAGTGAATTCTCTCTACTGAACC3′) (61). Alterna tively, groups of DENV1, YFV, or JEVimmune mice or controls were infected intraperitoneally with 1 × 10 6 PFU of DENV1. Spleens were harvested 5 days after infection for RNA isolation. RNA was extracted using TRIzol reagent (Invitrogen). Onestep quantitative PCR (qPCR) was performed using the SuperScript III Platinum OneStep qRTPCR Kit (Invitrogen), as recommend by the manufacturer. The primers and the probe from the SinglePlex and MultiPlex RTPCR for Detection and Serotype Identification of Dengue Virus [Centers for Disease Control and Prevention (CDC)] were used. A plasmid containing the DENV1 region of interest was used to generate a standard curve to quantify genome copies, and cDNA from uninfected mouse tissue was used as a negative control.
Generation flavivirus distribution maps
Current distributions of flaviviral pathogens were obtained from multiple recent sources including current literature (62) (63) (64) (65) , the World Health Organization, and CDC. The Google GeoChart tool and Adobe Illustrator software were used to generate the maps.
Phylogenetic analysis
For phylogenetic analysis, fulllength polyprotein amino acid se quences from DENV1, DENV2, DENV3, DENV4, JEV, ZIKV, WNV, Spondweni virus, and YFV were aligned using Clustal Omega or Molecular Evolutionary Genetic Analysis (MEGA) software. The phylogenetic tree was constructed by using the maximum like lihood method based on the JonesTaylorThornton (JTT) matrix based model. The tree with the highest log likelihood is shown. Initial tree(s) for the heuristic search was obtained automatically by applying NeighborJoin and BioNJ algorithms to a matrix of pair wise distances estimated using a JTT model and then selecting the topology with superior log likelihood value. The bootstrap test of phylogeny with 1000 repeats was performed, and the tree was drawn to scale, with branch lengths measured in the number of substitu tions per site. Evolutionary analyses were conducted using MEGA7 software (www.megasoftware.net).
MHC-II binding predictions
The MHCII binding predictions were made for the MHCII IAb locus on 1/25/2016 using the Immune Epitope Database Analysis Resource Consensus tool (66, 67) using the following protein sequences: DENV1 (GenBank: ABW82066.1), YFV (GenBank: AGO04419.1), and JEV (GenBank: BAA14219.1). Homologous protein sequences were identified by alignment using ClustalX 2.1 software. From the prediction, we selected DENV1 peptides with a percentile rank lower than 5 as predicted MHCII binding peptides. Six peptides of 15 amino acids length were selected for validation based on their characteristic of having significant likelihood of MHCII presentation for one or more of the flaviviruses used in this study: ASAWTLYAVATTIIT, RSGVLWDTPSPPEVE, AA IFMTATPPGSVEA, YKTWAYHGSYEVKPS, VILAGPMPVTVASAA, and AFLRFLAIPPTAGIL.
Human PBMC stimulation
PBMCs were isolated from the blood of donors that were either JEVvaccinated or JEVnaïve and were stored at −80°C until use. After thawing, PBMCs were seeded (1 million cells per well in a 96 well plate) and stimulated for 72 hours with DENV1, YFV, ZIKV, or control antigens (50 g/ml). The antigens were derived from cell culture to ensure the presence of nonstructural epitopes, as de scribed above and according to published protocols (60) . Before extracellular staining for surface markers, cells were treated with Fixable Viability Stain 510 (BD Biosciences, catalog no. 564406) ac cording to the manufacturer's instructions to indicate Live/Dead cells. Extracellular and intracellular staining of the PBMCs was performed, as previously described for staining of mouse cells, using the follow ing antibodies: mouse antihuman CD3 PerCPCy5.5 (BD Pharmingen, catalog no. 560835), mouse antihuman CD4 BUV395 (BD Bio sciences, catalog no. 742738), mouse antihuman CD8 BV650 (BD Biosciences, catalog no. 740587), mouse anti human CD27 BV786 (BD Biosciences, catalog no. 740972), mouse antihuman CD62L BV711 (BD Biosciences, catalog no. 740783), mouse antihuman CD38 BV605 (BD Biosciences, catalog no. 740401), mouse anti human CD45RO PECy7 (BD Biosciences, catalog no. 560608), mouse antihuman HLADR APCH7 (BD Biosciences, catalog no. 561358), and rat antihuman CD197 (CCR7) BV421 (BD Biosciences, catalog no. 740052). Data were acquired using a Fortessa flow cy tometer (BD Biosciences) and analyzed using FlowJo software.
Human ELISPOT assay
PBMCs from either JEVvaccinated or JEVnaïve donors were seeded at 1 million per well in a 96well plate and incubated for 48 hours at 37°C with 5% CO 2 . The PBMCs were stimulated with DENV1, YFV, ZIKV, or control antigen (50 g/ml). The PBMCs were then transferred to an IFN ELISPOT plate and incubated for 17 hours before detection following the manufacturer's instructions (Abcam, catalog no. ab46569). After plate scanning, the number of spotforming cells was enumerated by counting.
Statistical analysis
Statistical analyses were performed using GraphPad Prism or Micro soft Office Excel. For comparison between two groups, Student's unpaired t test was used. For multiple comparisons, oneway ANOVA was used with Dunnett's posttest. The differences were considered significant when P was <0.05. The strength of significance is presented as follows: *P < 0.05, **P < 0.01, and ***P < 0.001.
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